<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01091376</url>
  </required_header>
  <id_info>
    <org_study_id>ZhejiangCH02</org_study_id>
    <nct_id>NCT01091376</nct_id>
  </id_info>
  <brief_title>Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)</brief_title>
  <acronym>RT0901</acronym>
  <official_title>A Phase II Study of Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Concomitant chemoradiotherapy is the standard treatment of locally advanced,non-resectable,
      non-small cell lung cancer (NSCLC). However,the optimal chemotherapy regimen is still
      controversial.The objective of this study was to evaluate the efficacy and toxicity of a
      concomitant treatment using Erlotinib and radiotherapy followed by Erlotinib consolidation
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with non-resectable Non-small Cell Lung Cancer will receive thoracic radiation
      therapy 60-70 Gy over 30-35 fractions and concurrent with Erlotinib 150mg/day. Followed by
      Erlotinib 150 mg/day consolidation treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">March 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor response rate (Response was analyzed according to the RECIST system, based on CT scans.)</measure>
    <time_frame>After the thoracic radiotherapy and concurrent Erlotinib treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The safety (The safety was evaluated according to the National Cancer Institute Common Toxicity Criteria version 3.0.)</measure>
    <time_frame>Every one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>The time from the start of treatment to diease progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The overall survival</measure>
    <time_frame>The time from the start of treatment to death</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QoL was evaluated according to the FACT-L.)</measure>
    <time_frame>Every one month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Concomitant Erlotinib and radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received Erlotinib and radiation therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib</intervention_name>
    <description>Erlotinib 150mg/day</description>
    <arm_group_label>Concomitant Erlotinib and radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Thoracic radiotherapy</intervention_name>
    <description>60-70Gy/30-35f</description>
    <arm_group_label>Concomitant Erlotinib and radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically proven non-small cell lung cancer (squamous cell carcinoma,
             adenocarcinoma, large cell carcinoma and etc)

          -  Tumor EGFR mutation

          -  Presence of measurable disease by RECIST

          -  stage IIIA or IIIB, non-resectable

          -  ECOG performance status 0-2

          -  No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy

          -  Patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study in keeping with the policy of the hospital.

        Exclusion Criteria:

          -  Carcinoid tumor, small cell carcinoma of lung

          -  Patients with any distant metastasis

          -  History of another malignancy except cured basal cell carcinoma of skin and cured
             carcinoma in-situ of uterine cervix

          -  Any other morbidity or situation with contraindication for radiotherapy (e.g. active
             infection, myocardial infarction preceding 6 months, symptomatic heart disease
             including unstable angina, congestive heart failure or uncontrolled arrhythmias,
             immunosuppressive treatment)

          -  Pregnant or lactating women, women who has not taken test of pregnancy (within 7 days
             before the first administration) and pregnant women

          -  Women and men of childbearing potential who have no willing of employing adequate
             contraception

          -  Tumor EGFR wild
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shenglin Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cancer Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lvhua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shenglin Ma, MD</last_name>
    <phone>+8657188122568</phone>
    <email>mashenglin@medmail.com.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yaping Xu, MD</last_name>
    <phone>+8657188122082</phone>
    <email>xuyaping1207@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shenglin Ma, MD</last_name>
      <phone>+8657188122568</phone>
      <email>mashenglin@medmail.com.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yaping Xu, MD</last_name>
      <phone>+8657188122082</phone>
      <email>xuyaping1207@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shenglin Ma, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yaping Xu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>March 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2010</study_first_posted>
  <last_update_submitted>May 13, 2010</last_update_submitted>
  <last_update_submitted_qc>May 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Shenglin Ma, Lvhua Wang</name_title>
    <organization>Zhejiang Cancer Hospital; Chinese Academy of Medical Sciences Cancer Hospital</organization>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>EGFR-TKI</keyword>
  <keyword>Erlotinib</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

